Rubius Therapeutics, Inc. (RUBY)

NASDAQ: RUBY · IEX Real-Time Price · USD
0.280
+0.002 (0.68%)
Jan 27, 2023, 4:00 PM EST - Market closed

Income Statement (Annual)

Millions USD. Fiscal year is Jan - Dec.
Year 202120202019201820172016
Selling, General & Admin
53.0350.3457.1839.8922.042.45
Research & Development
141.59116.11112.4251.7721.238.4
Operating Expenses
194.62166.45169.691.6643.2610.85
Operating Income
-194.62-166.45-169.6-91.66-43.26-10.85
Interest Expense / Income
6.434.192.590.460.310.15
Other Expense / Income
-4.5-2.9-8.73-2.930.270.02
Pretax Income
-196.55-167.73-163.46-89.2-43.85-11.02
Net Income
-196.55-167.73-163.46-89.2-43.85-11.02
Preferred Dividends
00000.660.75
Net Income Common
-196.55-167.73-163.46-89.2-44.5-11.76
Shares Outstanding (Basic)
8881793987
Shares Outstanding (Diluted)
8881793987
Shares Change
9.09%2.46%100.30%389.61%11.43%-
EPS (Basic)
-2.23-2.08-2.08-2.27-5.55-1.63
EPS (Diluted)
-2.23-2.08-2.08-2.27-5.55-1.63
Free Cash Flow Per Share
-1.69-1.65-1.92-1.87-3.02-1.38
EBITDA
-182.39-157.86-157.87-87.47-43.09-10.75
Depreciation & Amortization
7.725.6931.260.450.12
EBIT
-190.11-163.55-160.87-88.73-43.54-10.87
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).